Please login to the form below

Not currently logged in
Email:
Password:

EFPIA's Richard Torbett to move to the ABPI

Will take up commercial role at UK pharma bodyat the end of the month

ABPI Richard TorbettThe Association of the British Pharmaceutical Industry (ABPI) has appointed Richard Torbett as executive director - commercial UK.

He will take up the role at the end of this month, moving from European pharma trade association EFPIA, where he was chief economist and director of strategy.

Prior to this Torbett spent six years at Pfizer, where he was a senior director and head of international affairs.

In his new role Torbett will be responsible for heading up the ABPI's commercial strategy and leading its UK commercial team, and will report to the ABPI's chief executive.

Alison Clough, acting CEO, said: “With his wealth of knowledge and expertise, Richard will be very well placed to direct the ABPI's commercial strategy and to lead the UK commercial team.

“His experience in both government and the pharmaceutical industry will prove invaluable when addressing the issues of access and use of new medicines in the NHS and in leading discussions with the Department of Health around the PPRS.”

At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.

22nd July 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics